Creative Biolabs adds multi-platform support for brain-immune-gut axis research

Creative Biolabs has expanded its research support for studies of the brain-immune-gut axis, offering integrated workflows that combine microbial manipulation, neural tissue handling and immune profiling. The company says the platform is aimed at improving mechanistic studies in neurodegeneration, neuroinflammation and related fields.

Why it matters: - Brain-immune-gut research depends on models that can capture interactions between peripheral biology and the brain. - Creative Biolabs is positioning an integrated workflow to help researchers study those interactions with more control over microbial, immune and neural variables. - The service is aimed at applications in neurodegenerative disease, neuroinflammation, central nervous system oncology, gut microbiota screening and mucosal barrier research.

What happened: - Creative Biolabs announced enhanced support for brain-immune-gut axis regulation research. - The company said the offering combines advanced gut microbiome modulation with multi-platform experimental workflows. - The announcement was dated July 17, 2026, in Shirley, New York.

The details: - The service is built around four workflow stages: model preparation, in vivo microbial intervention, neural cell or tissue harvest, and downstream functional testing. - Creative Biolabs supports targeted phyla depletion, metabolomics profiling, primary cell isolation, scaffold-based or organotypic brain slice processing, and automated immune biomarker validation. - Typical deliverables may include a customized microbial intervention protocol, validated cellular assay profiles, specific metabolic quantification data and recommendations for therapeutic development. - The company also offers comprehensive microglial activation characterization. - That workflow can include ELISA and ELISPOT for cytokine production measurement, including TNF-α, IL-1β and IL-6. - Additional tools include Western Blot and FACS for phenotypic marker expression, colorimetric assays for nitric oxide release, and fluorescence metrics for real-time ROS or calcium mobilization monitoring. - The company says researchers can use more information on integrated Brain–Immune–Gut Axis research capabilities through Creative Biolabs.

Between the lines: - The announcement reflects growing interest in multi-dimensional in vitro systems that can better reproduce selected structural and functional interactions than standalone cell models. - Creative Biolabs is framing the platform as a way to reduce variability and improve reproducibility in complex biological studies. - The company is also emphasizing end-to-end support rather than offering isolated microbiome or immune assay services.

What's next: - Creative Biolabs expects integrated multi-platform research tools to play a larger role as demand rises for mechanistic insight into the brain-immune-gut connection. - Researchers using the service can move from microbial intervention to tissue analysis and immune validation within a connected workflow. - The company says the approach is designed to support discovery pipelines that are more consistent and more application-focused.

The bottom line: - Creative Biolabs is bundling microbiome control, neurobiology assays and immune profiling into one research platform for BIG axis studies.